{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:17Z","timestamp":1792782677486,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900145"],"award-info":[{"award-number":["81900145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270158"],"award-info":[{"award-number":["82270158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["1Y31920402"],"award-info":[{"award-number":["1Y31920402"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Clinical Research Center for Cell Therapy","award":["23J41900100"],"award-info":[{"award-number":["23J41900100"]}],"id":[{"id":"https:\/\/ror.org\/057tkkm33","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07120-y","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:53:53Z","timestamp":1781142833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yuyang","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"24","key":"7120_CR1","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","volume":"316","author":"T Philip","year":"1987","unstructured":"Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med 316(24):1493\u20131498. https:\/\/doi.org\/10.1056\/NEJM198706113162401","journal-title":"N Engl J Med"},{"issue":"9323","key":"7120_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359(9323):2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"issue":"1","key":"7120_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/blood.V73.1.340.340","volume":"73","author":"JG Gribben","year":"1989","unstructured":"Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin\u2019s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73(1):340\u2013344","journal-title":"Blood"},{"issue":"7","key":"7120_CR4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00277-024-05813-w","volume":"103","author":"R Wang","year":"2024","unstructured":"Wang R, Shangguan X, Zhu Z, Cong D, Bai Y, Zhang W (2024) BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL. Ann Hematol 103(7):2455\u20132462. https:\/\/doi.org\/10.1007\/s00277-024-05813-w","journal-title":"Ann Hematol"},{"key":"7120_CR5","doi-asserted-by":"publisher","unstructured":"Carranza J, Fatobene G, Otuyama LJ, Dos Santos JG, Cordeiro AC, Mariano L et al (2024) Early toxicity and efficacy of four different conditioning regimens for autologous hematopoietic cell transplantation in patients with lymphoma: impact of drug shortages in a resource-constrained country. Transplant Cell Ther 30(10):1003 e1001-1003 e1009. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.025","DOI":"10.1016\/j.jtct.2024.07.025"},{"issue":"5","key":"7120_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00280-015-2866-9","volume":"76","author":"B You","year":"2015","unstructured":"You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V et al (2015) Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Cancer Chemother Pharmacol 76(5):939\u2013948. https:\/\/doi.org\/10.1007\/s00280-015-2866-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"7120_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s1083-8791(01)70015-8","volume":"7","author":"MJ Stuart","year":"2001","unstructured":"Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ et al (2001) Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin\u2019s disease. Biol Blood Marrow Transpl 7(10):552\u2013560. https:\/\/doi.org\/10.1016\/s1083-8791(01)70015-8","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"7120_CR8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","volume":"24","author":"J Olivieri","year":"2018","unstructured":"Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M et al (2018) A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Biol Blood Marrow Transpl 24(9):1814\u20131822. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8852","key":"7120_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341(8852):1051\u20131054. https:\/\/doi.org\/10.1016\/0140-6736(93)92411-l","journal-title":"Lancet"},{"issue":"7","key":"7120_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","volume":"22","author":"CR Flowers","year":"2016","unstructured":"Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB et al (2016) Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transpl 22(7):1197\u20131205. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"7120_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/1042819031000083028","volume":"44","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Kuittinen T, Nousiainen T (2003) BEAC or BEAM for high-dose therapy in patients with non-Hodgkin\u2019s lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 44(7):1151\u20131158. https:\/\/doi.org\/10.1080\/1042819031000083028","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"7120_CR12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1080\/10428190500527769","volume":"47","author":"N Puig","year":"2006","unstructured":"Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L et al (2006) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 47(8):1488\u20131494. https:\/\/doi.org\/10.1080\/10428190500527769","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7120_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/16078454.2022.2051864","volume":"27","author":"L Zhang","year":"2022","unstructured":"Zhang L, Yang H, Qian C, Zhou J, Zhu Q, Jiang Y et al (2022) Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma. Hematology 27(1):404\u2013411. https:\/\/doi.org\/10.1080\/16078454.2022.2051864","journal-title":"Hematology"},{"issue":"1","key":"7120_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12185-024-03755-7","volume":"120","author":"S Zhou","year":"2024","unstructured":"Zhou S, Rao J, Ma X, Zeng Y, Xiang X, Li J et al (2024) Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas. Int J Hematol 120(1):96\u2013105. https:\/\/doi.org\/10.1007\/s12185-024-03755-7","journal-title":"Int J Hematol"},{"issue":"12","key":"7120_CR15","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood 118(12):3419\u20133425. https:\/\/doi.org\/10.1182\/blood-2011-04-351924","journal-title":"Blood"},{"issue":"2","key":"7120_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00277-023-05513-x","volume":"103","author":"T Wang","year":"2024","unstructured":"Wang T, Liu P, Xu L, Gao L, Ni X, Tang G et al (2024) CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients. Ann Hematol 103(2):575\u2013582. https:\/\/doi.org\/10.1007\/s00277-023-05513-x","journal-title":"Ann Hematol"},{"key":"7120_CR17","doi-asserted-by":"publisher","first-page":"963689723117936","DOI":"10.1177\/09636897231179364","volume":"32","author":"R Wu","year":"2023","unstructured":"Wu R, Ma L (2023) BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transpl 32:9636897231179364. https:\/\/doi.org\/10.1177\/09636897231179364","journal-title":"Cell Transpl"},{"key":"7120_CR18","doi-asserted-by":"publisher","first-page":"102318","DOI":"10.1016\/j.eclinm.2023.102318","volume":"66","author":"F Keil","year":"2023","unstructured":"Keil F, Muller AMS, Berghold A, Riedl R, Buxhofer-Ausch V, Schuster J et al (2023) BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial. EClinicalMedicine 66:102318. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102318","journal-title":"EClinicalMedicine"},{"issue":"3","key":"7120_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41409-018-0328-9","volume":"54","author":"ES Tsang","year":"2019","unstructured":"Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci B et al (2019) High-dose Benda-EAM versus BEAM in patients with relapsed\/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transpl 54(3):481\u2013484. https:\/\/doi.org\/10.1038\/s41409-018-0328-9","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"7120_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00277-016-2900-y","volume":"96","author":"S Gilli","year":"2017","unstructured":"Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y et al (2017) BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol 96(3):421\u2013429. https:\/\/doi.org\/10.1007\/s00277-016-2900-y","journal-title":"Ann Hematol"},{"issue":"5","key":"7120_CR21","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/ajco.12610","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi Y, Liu P, Zhou S, Yang J, Han X, He X et al (2017) Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity. Asia Pac J Clin Oncol 13(5):e423\u2013e429. https:\/\/doi.org\/10.1111\/ajco.12610","journal-title":"Asia Pac J Clin Oncol"},{"issue":"19","key":"7120_CR22","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2014-08-596668","volume":"124","author":"G Visani","year":"2014","unstructured":"Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al (2014) Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 124(19):3029\u20133031. https:\/\/doi.org\/10.1182\/blood-2014-08-596668","journal-title":"Blood"},{"issue":"3","key":"7120_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1600-0609.2008.01096.x","volume":"81","author":"M Caira","year":"2008","unstructured":"Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT et al (2008) Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 81(3):242\u2013243. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01096.x","journal-title":"Eur J Haematol"},{"issue":"6","key":"7120_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/myc.12161","volume":"57","author":"A Candoni","year":"2014","unstructured":"Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R et al (2014) Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 57(6):342\u2013350. https:\/\/doi.org\/10.1111\/myc.12161","journal-title":"Mycoses"},{"issue":"3","key":"7120_CR25","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.13879","volume":"9","author":"A Cuomo","year":"2022","unstructured":"Cuomo A, Mercurio V, Varricchi G, Galdiero MR, Rossi FW, Carannante A et al (2022) Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Fail 9(3):1666\u20131676. https:\/\/doi.org\/10.1002\/ehf2.13879","journal-title":"ESC Heart Fail"},{"issue":"9","key":"7120_CR26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/echo.13278","volume":"33","author":"V Schiano-Lomoriello","year":"2016","unstructured":"Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A et al (2016) Longitudinal strain of left ventricular basal segments and E\/e\u2019 ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography 33(9):1335\u20131343. https:\/\/doi.org\/10.1111\/echo.13278","journal-title":"Echocardiography"},{"issue":"7","key":"7120_CR27","first-page":"794","volume":"88","author":"M Picardi","year":"2003","unstructured":"Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V et al (2003) Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 88(7):794\u2013800","journal-title":"Haematologica"},{"issue":"11","key":"7120_CR28","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/blood.v99.11.4228","volume":"99","author":"M Picardi","year":"2002","unstructured":"Picardi M, Martinelli V, Ciancia R, Soscia E, Morante R, Sodano A et al (2002) Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood 99(11):4228\u20134230. https:\/\/doi.org\/10.1182\/blood.v99.11.4228","journal-title":"Blood"},{"key":"7120_CR29","doi-asserted-by":"publisher","unstructured":"Atacan H, Aslan V, Topal A, Mammadzada N, Yildirim G, Guneysu GG et al (2026) Pre-transplant prognostic nutritional index independently predicts progression-free survival after autologous stem cell transplantation in lymphoma. J Clin Med 15(9). https:\/\/doi.org\/10.3390\/jcm15093549","DOI":"10.3390\/jcm15093549"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07120-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07120-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07120-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:01:56Z","timestamp":1789509716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07120-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7120"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07120-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the Ethics Committee of Shanghai Ninth People\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"374"}}